Fed Sparks Profit T...
Health Care: Drugs
Apricus Biosciences Inc. (APRI: NASDAQ)
$2.60 -0.06 | -2.08%
05/24/13 - 12:16 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 2.65 |
| 52 Week High | 3.63 |
| 52 Week Low | 1.89 |
| Avg. Daily Vol. (Mil) | 0.29 |
| Beta (3 year) | 2.67 |
| Share Related Items | |
| Mkt Cap (Mil) | 80.94 |
| Shares Out (Mil) | 30.54 |
| Float (Mil) | 30.08 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.40 |
| Current Ratio | 1.50 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 9.35 |
| Price/Book | 0.00 |
| Price/Cash Flow | -2.00 |
| Per Share Data | |
| Earnings | -1.27 |
| Sales | 0.28 |
| Book Value | 0.00 |
| Cash Flow | -1.32 |
| Business Summary | |
|---|---|
| Apricus Biosciences, Inc., is a pharmaceutical company, develops and commercializes pharmaceutical products that treat large patient populations with operations based in the United States. | |
| General Information | |
| 11975 El Camino Real
Suite 300 San Diego, CA 92130 |
|
| www.apricusbio.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 114 | |
| CEO: Richard W. Pascoe | |
| Short Interest | |
| Current Month (Mil) | 3.01 |
| Previous Month (Mil) | 2.94 |
| Short Interest Ratio (Days) | 15.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -243.20 |
| Return on Investments | -145.00 |
| Profitability | |
| Gross Margin | -66.00 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with APRI
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
Latest APRI Headlines from TheStreet
- Apricus Biosciences Prices $17.1 Million Public Offering Of Common Stock And Warrants 05.23.13 | 09:05 am
- Apricus Biosciences Announces Proposed Public Offering Of Common Stock And Warrants 05.22.13 | 04:05 pm
- Apricus Biosciences Provides First Quarter 2013 Corporate Update 05.10.13 | 08:05 am
- Apricus Biosciences Announces First Quarter 2013 Financial Results Conference Call 05.07.13 | 02:05 pm
- Apricus Biosciences Announces Poster Presentation Of Vitaros(R) Data In Men Previously Unresponsive To PDE-5 Inhibitors At American Urological Association Annual Meeting 05.07.13 | 11:05 am
- Apricus Biosciences To Present At 2013 BIO International Convention 04.18.13 | 07:04 am
- Apricus Biosciences Announces Sale Of Non-Core Assets 04.01.13 | 04:04 pm
- Apricus Biosciences Provides Corporate Update; Files Annual Report For Quarter And Year Ended December 31, 2012 03.18.13 | 11:03 am
- Apricus Biosciences Appoints Richard W. Pascoe As Chief Executive Officer 03.18.13 | 11:03 am
- Apricus Biosciences Announces 2012 Year End Financial Results Conference Call 03.14.13 | 09:03 am
Press Releases for APRI
- Apricus Biosciences, Inc. (APRI) Transforms From Development Company To Income Generating! - PR Newswire 03.14.12 | 09:03 am
- Apricus Biosciences To File For Market Authorization To Sell Vitaros® For Erectile Dysfunction In Latin America - PR Newswire 08.08.11 | 07:08 pm
- Apricus Biosciences Launches Educational Video Series Focused On Its Newly Approved Erectile Dysfunction Drug, Vitaros® - Business Wire 12.06.10 | 09:12 am
- Apricus Biosciences Appoints Manufacturer For Vitaros®, Its Newly Approved Drug To Treat Erectile Dysfunction In Canada - Business Wire 12.01.10 | 10:12 am
- Apricus Biosciences Announces New NexACT® Transbuccal Delivery Data Published In The International Journal Of Pharmaceutics - Business Wire 11.29.10 | 10:11 am
- Apricus Biosciences Files Phase 3 Registration Protocol For PrevOnco™ For Special Protocol Assessment Consideration By The FDA - Business Wire 11.22.10 | 10:11 am
- Apricus Bio Announces Pre-Clinical Data Showing Significant Improvement In Solubility And Absorption Of NexACT®-Based Small Molecule Drugs Selected From The Biopharmaceutics Classification System - Business Wire 11.19.10 | 10:11 am
- Apricus Biosciences’ CEO Bassam Damaj, Ph.D., Interviewed By The Financial Network CDTV.net - Business Wire 11.17.10 | 10:11 am
- Apricus Biosciences Receives Canadian Approval For Vitaros® As First Line Therapy For Erectile Dysfunction - Business Wire 11.15.10 | 12:11 pm
- Apricus Biosciences Announces 2010 Third Quarter Financial Results Conference Call - Business Wire 11.10.10 | 10:11 am
Partner Headlines for APRI
- Smart Stocks Watch: Apricus Biosciences - Seeking Alpha 09.21.12 | 09:09 am
- Apricus, Takeda Ink Marketing Deal - Analyst Blog - NASDAQ 09.14.12 | 10:09 pm
- Apricus, Takeda Ink Marketing Deal - Analyst Blog - Zacks 09.14.12 | 06:09 pm
- Tesaro Initiated at OUTPERFORM and 2 Initiated Shares on the Move - Wall St. Cheat Sheet 07.23.12 | 04:07 am
- REVEALED: New Stock Analyst Coverage to Evaluate - Wall St. Cheat Sheet 06.14.12 | 03:06 am
- Apricus Biosciences Strengthens Vitaros and Nexact Patent Estate With Two New Patent Allowances - Benzinga 05.25.12 | 01:05 pm
- Apricus Biosciences Granted Regulatory Meeting With FDA for Femprox(R) for the Treatment of Female Sexual Arousal Disorder - Benzinga 05.21.12 | 09:05 am
- Health Canada Grants Apricus Biosciences Pre-NDS Meeting for MycoVa(TM) for the Treatment of Onychomycosis - Benzinga 05.11.12 | 09:05 am
- Apricus Biosciences; Vitaros Has Great Potential - Seeking Alpha 04.22.12 | 09:04 am
- Apricus Biosciences and Elis Pharma Sign License Agreement for MycoVa in the Middle East and the Gulf - Benzinga 01.10.12 | 09:01 am
